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Abstract
A series of newly synthesized hydroxylated analogues of triethyldesmosdumotin B (TEDB) with a 
bicyclic B-ring exhibited a significantly different mode of action for affecting microtubule 
dynamics and spindle formation but had the same antiproliferative activity spectrum, including 
activity against multidrug-resistant tumors. These analogues efficiently induced cell cycle arrest at 
prometaphase and caused formation of immature multipolar spindles. 6′-Hydroxyl TEDB-TB (8) 
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disrupted bipolar spindle formation but had a negligible effect on interphase microtubules. On the 
basis of the predicted binding modes of the new compounds with tubulin dimer, compound 4 
forms three hydrogen bonds (H-bonds) only with α-tubulin at the colchicine site; in contrast, 8 
forms H-bonds with both α- and β-tubulin. We predict that, when a compound/ligand, such as 8, 
forms H-bonds to both α- and β-tubulins, spindle formation is disrupted more than the dynamics 
of interphase microtubules. This result may reflect the well-known greater dynamicity of spindle 
microtubules as compared with interphase microtubules.
1. INTRODUCTION
Microtubule-targeting agents are recognized as valuable drugs in the treatment of both solid 
cancers and hematologic malignancies.1–3 Antimicrotubule agents disrupt microtubule 
dynamics, resulting in disruption of cell cycle progression and, subsequently, induction of 
cell death. On the basis of the mechanisms of action, antimicrotubule agents are normally 
categorized into two groups: (i) microtubule disrupters that inhibit the polymerization of 
tubulin, such as colchicine, vincristine (VIN), podophyllotoxin, and combretastatin A-4 
(CA-4), and (ii) microtubule stabilizers that prevent the depolymerization of microtubules, 
such as paclitaxel (PXL), epothilones, discodermolide, and laulimalide. Depending on their 
binding domain on tubulin, these antimitotic agents are further classified into (i) colchicine 
site agents (CSAs), such as colchicine and CA-4; (ii) vinca site agents, such as VIN and 
vinblastine; (iii) taxane site (on the microtubule interior) agents, such as PXL and 
epothilones; (iv) laulimalide site (on the microtubule exterior) agents, such as laulimalide 
and peloruside A; and (v) others.4 Importantly, numerous antimicrotubule agents have been 
identified and developed from natural products. Antimicrotubule agents, especially taxanes 
and vinca alkaloids, are commonly used in clinical cancer treatment. Furthermore, many 
microtubule-targeting natural products are currently in clinical trials. However, although 
antimicrotubule agents are quite useful cancer chemotherapeutics, one major obstacle 
remains unsolved: innate and acquired drug resistance, notably multidrug resistance (MDR). 
The best-known gene is MDR-1, encoding P-glycoprotein (P-gp). Overexpression of the P-
gp drug transporter leads to poor disease prognosis,5–9 and most clinical antimicrotubule 
drugs are P-gp substrates. [A survey of numerous antimicrotubule agents with a single 
matched pair of cells, with one of the lines overexpressing P-gp, demonstrated that PXL, 
docetaxel, ixabepilone, VIN, vinblastine, vinorelbine, and the truncated halichondrin B 
analogue eribulin were P-gp substrates (Hamel and R. Bai, unpublished data).] A recent 
study indicated that overexpression of class III β-tubulin, as well as changes in microtubule 
regulation, are also associated with MDR to antimicrotubule agents that interact with the 
taxane or vinca site.10 However, interestingly, CSAs were generally active in cells 
overexpressing class III β-tubulin.11
Although rapidly growing cells, such as tumors, are sensitive to antimicrotubule agents, 
normal cells are also impacted by disruption of microtubule networks. Because no CSAs are 
currently used clinically for cancer treatment, the discovery of new antimitotic agents 
targeting the colchicine site (CS) might be a valuable approach for effective cancer 
chemotherapy, especially agents that can overcome the MDR phenotype without interfering 
with interphase microtubule dynamics.
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Desmosdumotin B (DesB, 1), a flavonoid with an unusual nonaromatic trimethylated A-ring 
(Figure 1), exhibited unique bioactivity against P-gp overexpressing MDR tumor cells. 
Briefly, 1 displayed selective antiproliferative activity against tumor cell lines 
overexpressing P-gp, while it was nontoxic against non-MDR tumor cell lines. Its selective 
index (SI), the IC50 against non-MDR cells divided by the IC50 against MDR cells, was >20. 
This selectivity against MDR lines was greatly enhanced by triethylation of the A-ring, 
producing 2 (TEDB, SI > 220) and 3 (SI = 490).12–14 The TEDB analogues with a bicyclic 
aryl B-ring, such as benzo[b]thiophene 4 (TEDB-TB) and naphthalene 5, displayed a 
dramatically different bioactivity profile, showing substantial growth inhibition against 
multiple cancer cell lines.13,15 These analogues inhibited tubulin polymerization, in part 
through the CS. Importantly, none of the analogues were P-gp substrates, and thus, they may 
be potentially effective against MDR tumors.15
Poor water solubility is another major obstacle for the use of antimitotic agents, especially 
the taxanes.2 Generally, the incorporation of a hydroxyl group into a structure can lead to 
increased polarity as well as polar surface area (PSA), which is connected to oral 
bioavailability16 and correlated with passive intestinal absorption.17,18 cLogP has been used 
as a parameter of water solubility. In the TEDB-TB series, cLogP values of the related 
hydroxyl analogues were reduced by a range of 0.5–0.9 from those of the parent compounds 
(Supporting Information, Table S1).19 In a prior modeling study, the structure of TEDB-TB 
partially matched with the common pharmacophores conserved in antimicrotubule CSAs.15 
This same study also suggested that a hydrogen acceptor, such as a hydroxyl group, on the 
B-ring in TEDB-TB could contribute to an additional common CS-related pharmacophore. 
Inspired by these analyses, we rationally designed and synthesized various hydroxyl 
analogues of 4 and 5 to improve water solubility, as well as to study structure–activity 
relationships (SARs). A hydroxyl group also allows various functional groups to be 
introduced into the compound in future modification studies. All synthesized analogues 
were evaluated for antiproliferative activity against several cancer cell lines, including an 
MDR tumor cell line. Active analogues were further assessed for potential effects against 
tubulin assembly in a cell-free system and cell cycle progression in tumor cells. We also 
performed molecular modeling studies with the analogues bound to tubulin, and these 
demonstrated a novel mode of H-bond formation in the CS.
In this paper, we describe the syntheses of a series of hydroxyl analogues of 4 and 5 and the 
bioactivities of these compounds. We also summarize our molecular modeling results.
2. RESULTS AND DISCUSSION
Chemistry
Hydroxylated analogues 6–20 (Figure 2) were prepared from 2-acetyl-4,4,6-triethyl-3-
hydroxy-5-methoxycy-clohexa-2,5-dien-1-one (21) using our prior synthetic methodology to 
produce TEDB (2),12–14 as shown in Scheme 1. A Claisen-Schmidt condensation of 21 with 
various methoxybenzo[b]thiophenecarboxaldehydes 24–28 or commercially available 
methoxynaphthaldehydes 29–31 provided the related chalcones 22 in good yield. The 
resulting chalcones were cyclized in the presence of catalytic iodine and concd H2SO4. 
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Demethylation of 23 with BBr3 produced the desired hydroxyl analogues 6–9, 14–16, and 
19. Methoxy analogues 10–12 were obtained as minor products during the demethylation 
step. Depending on the reaction conditions, the methoxy group on the A-ring was removed 
faster than that on the B-ring. Compounds 13, 17, 18, and 20 were previously synthesized.15 
The required benzo[b]thiophene aldehydes 24–27 were constructed as shown in Scheme 2. 
The condensation of p-, m-, and o-methoxybenzenethiols (32–34) with α-chloro ketone, 
followed by cyclization with polyphosphoric acid at 100 °C, afforded 5-methoxy-3-
methylbenzo[b]thiophenes (35) from 32, 4- and 6-methoxy derivatives (36 and 37) from 33, 
and the 7-methoxy derivative (38) from 34.20 The C-3 methyl group of 35–38 was converted 
by radical bromination to a bromomethyl group, which was then formylated by using a 
Sommelet reaction to obtain the desired 3-carboxaldehydes 24–27.21 On the other hand, 3-
bromobenzo[b]thiophene (43) was converted to 3-methoxybenzo[b]thiophene (44),22 which 
was formylated with DMF through 2-lithiation to obtain 2-carbaldehyde 28.
Antiproliferative Effects and SAR Analysis
All new analogues were evaluated for antiproliferative activity against 10 human tumor cell 
lines: KB (originally isolated from epidermoid carcinoma of the nasopharynx), KB-subline 
KB-VIN showing MDR phenotype with overexpression of P-gp, PC-3 (prostate cancer), 
A549 (lung carcinoma), HepG2 (hepatocellular carcinoma), HCT-8 (colon 
adenocarcinoma), and four breast cancer cell lines (MDA-MD-231, SK-BR-3, MCF-7, and 
ZR-75-1) (Table 1). The antiproliferative effects of the compounds were assessed by the 
sulforhodamine B (SRB) assay, and IC50 values were calculated from at least three 
independent experiments, each performed in duplicate.
Among the benzo[b]thiophen-3′-yl analogues, all four hydroxyl derivatives 6–9 showed 
potent antiproliferative effects against the tested tumor cell lines, including the P-gp-
overexpressing MDR tumor cell line. In contrast, the corresponding methoxy derivatives 
10–12 were less active. The position of the hydroxyl group on the B-ring had a strong 
influence on activity against HCT-8 tumor cells. Compared with 6 and 8, hydroxyl 
analogues 7 and 9, which have a hydroxy group at the para- or ortho-position, respectively, 
relative to the sulfur atom, exhibited more than 5-fold reduced inhibitory effect against 
HCT-8, while the activity against the other tumor cell lines was not noticeably affected. The 
3′-hydroxybenzo-[b]thiophen-2′-yl analogue 14 showed similar cytotoxicity to the 
nonhydroxylated parent compound 13 against all tested tumor cell lines except PC-3, against 
which 14 displayed 4-fold reduced activity.
In the case of the 1′-naphthyl derivatives, the insertion of a hydroxyl group on 15 and 16 
generally resulted in slightly better antiproliferative activity as compared with parent 
compound 5. This trend was not seen in the benzo[b]-thiophene analogues. In particular, the 
antiproliferative effects of 16 against HepG2, KB, and KB-VIN were 2–6 times greater than 
that of the parent compound 5. In addition, unlike the benzo[b]thiophene analogues, 
methoxynaphthalene derivative 17 also inhibited tumor cell growth with IC50 values of 1.5–
3.6 µM. These values differed little from those obtained with the related hydroxyl derivative 
16. The hydroxynaphthalen-2′-yl derivative 19 was generally 10-fold less active than the 
hydroxynaphthalen-1′-yl derivatives 15 and 16, while no differences were found between 
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the activities of 5 (naphthalen-1′-yl) and 18 (naphthalen-2′-yl). Overall, in this flavonoid 
series, the results indicated that the addition of a hydroxyl functionality to a bicyclic B-ring 
system on the first ring directly connected to the chromene skeleton caused slightly 
enhanced activity, although addition of a hydroxyl group on the second ring not directly 
connected to the chromene skeleton generally reduced activity. This SAR study is 
summarized in Figure 3.
Importantly, all analogues displayed potent antiproliferative effects against KB-VIN, a 
MDR KB subline overexpressing Pgp. The antiproliferative activities of 7–10, 12–14, 16, 
and 19 against KB-VIN were even greater than those against the parent KB non-MDR tumor 
cell line. This fact indicates that these analogues are not P-gp substrates and could be 
effective against tumors expressing the MDR phenotype.
Inhibition of Tubulin Polymerization and Colchicine Binding to Tubulin
Cytotoxic analogues 4–9 and 15–18 were tested for inhibitory effects on tubulin assembly as 
well as inhibition of [3H]colchicine binding to tubulin, using highly purified bovine brain 
tubulin. Table 1 lists the 50% effective concentration for inhibiting tubulin assembly (EC50-
ITA) and the percent inhibition of colchicine binding to tubulin (ICB) in the presence of 
compounds 4–9 and 15–18, as well as results obtained with the CS antimicrotubule agent 
CA-4 as a positive control. Standard deviations can be found in the Supporting Information. 
Analogue 6 with a 4′-hydroxyl strongly inhibited tubulin assembly with an EC50-ITA value 
of 2.8 µM and inhibited colchicine binding by 70%. The data for 4 and 6 were very similar, 
despite the more than 10-fold difference in their antiproliferative effects against tumor cells. 
These results suggest that both compounds bind to tubulin and inhibit its polymerization, 
while 6 may be detoxified in the tumor cells more rapidly than 4. The disparate results 
between antiproliferative and tubulin inhibitory effects were also observed for other 
analogues. 4′-Hydroxyl analogue 6 and 6′-hydroxyl analogue 8 comparably inhibited tumor 
cell growth, but the inhibitory effects on tubulin assembly and colchicine binding of 6 were 
2-fold greater than those of 8. These results prompted us to perform additional investigations 
on hydroxyl analogs 6 and 8, as well as 4, using human tumor cell lines. It should be noted 
that original natural product 1 showed no effects on tubulin assembly in a cell-free system 
(Table 1) or in KB-VIN cells (data not shown).
Induction of Cell Cycle Arrest at the G2/M Phase in MDR Tumor Cells
Small molecules showing antimicrotubule activity, such as colchicine, VIN, and PXL, 
inhibit cell cycle progression at the G2/M phase in chemosensitive tumors. However, these 
compounds are ineffective against MDR tumors, because overexpressed ABC transporter(s) 
efficiently efflux these compounds.5 To see if the newly synthesized compounds affected the 
cell cycle in MDR tumor cells, the cell cycle progression of treated KB-VIN and parental 
KB cells was analyzed by flow cytometry (Figure 4). PXL at 0.02 µM significantly impacted 
the cell cycle in KB cells, while PXL at 3 µM did not show any effect in the KB-VIN cells, 
demonstrating that PXL is efficiently effluxed from the MDR tumor cell by overexpressed 
P-gp. In contrast, accumulation of cells in the G2/M phase, as well as the S-phase, was 
observed in both chemosensitive (KB) and MDR cells (KB-VIN) treated with 4 and its 
analogues at identical concentrations. Cell cycle progression was also disrupted by 
Nakagawa-Goto et al. Page 5
J Med Chem. Author manuscript; available in PMC 2016 March 12.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
compounds in a time-dependent manner. These results support the data found in the 
antiproliferative assays (Table 1) and indicate that MDR cells do not efflux 4 and its 
analogues.
Morphological Variations of Microtubule Dynamics by Antimicrotubule Agents in Tumor 
Cells
In the current study, immunofluorescence visualization of tubulin in PC-3 cells was used to 
clearly show distinguishable disruptions of microtubule dynamics upon treatment with 
different anti-microtubule agents binding to diverse sites, such as CA-4 binding to the CS, 
VIN binding to the vinca site, and PXL binding to the taxane site (Figure 5). In particular, 
microtubule morphology in mitotic PC-3 cells treated with 4 was not identical to those in 
mitotic cells treated with other tested antimicrotubule agents, while it was similar to that in 
interphase cells treated with CA-4 (Supporting Information, Figure S1). These results 
suggest that the mode of action of 4 is to inhibit tubulin polymerization in the interphase by 
a mechanism similar to that of CA-4, but different from CA-4 at the time of mitotic spindle 
formation.
Modification Sites in TEDB Skeleton Have Differing Effects on Microtubule Polymerization
To further understand the effects of the new hydroxyl-modified 4 analogues on microtubule 
dynamics and on the cell cycle, dose-dependent morphological microtubule defects were 
analyzed in PC-3 cells (Figure 6; Supporting Information, Figure S2). Flow cytometric 
analysis clearly demonstrated that all hydroxylated 4 analogues induced significant cell 
cycle accumulation in the G2/M phase (Figure 6A). To determine whether the cell cycle 
arrest was due to an antimicrotubule effect, cells treated with compound were analyzed by 
triple staining with antibodies to α-tubulin and the mitotic marker Ser10-phosphorylated 
histone H3 (p-H3) and with 4′,6-diamidino-2-phenylindole (DAPI) for DNA. In cells treated 
with compounds, multiple spindles were seen in the p-H3 positive cells (Figure 6B,C). The 
results demonstrated that the new compounds inhibited normal bipolar spindle formation 
and induced cell cycle arrest at the G2/M phase, probably at prometaphase. However, the 
impact of 4 analogues on spindle formation was different from that of other antimicrotubule 
agents. While multipolar spindles formed partially in cells treated with test compounds, no 
spindles were detected after treatment with CA-4 or PXL (Figure 6B,C and Supporting 
Information, Figure S2). While inhibition of spindle formation corresponded directly to 
depolymerization of interphase microtubules in cells treated with CA-4 or with 4, 6, or 9, 
disrupted spindle formation was observed in conjunction with normally polymerized 
interphase microtubules in cells treated with 7 or 8. Compound 7 was less active than 8. 
Furthermore, analysis of microtubule morphology in the presence of different doses of 8 
demonstrated that the normal morphology of interphase microtubules in the presence of 8 
did not result from partial inhibition of tubulin polymerization. Interestingly, stabilized 
interphase microtubules were observed in cells treated with a high concentration (20 µM) of 
7 or 8. Thus, compounds 7 and 8 selectively disrupted spindle formation without 
depolymerizing interphase microtubules (Figure 6B,C and Supporting Information, Figure 
S2). In contrast, using CA-4, it was not possible to determine a concentration that was less 
effective against interphase microtubule polymerization than spindle formation. At the 
concentration of CA-4 that inhibited interphase microtubule polymerization, accumulated p-
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H3 (Ser10)-positive cells showed no spindle formation. These cell-based observations 
suggested that compounds 7 and 8, especially 8, are more effective against the more 
dynamic spindles than the less dynamic interphase microtubules and, thus, interact with 
tubulin in a manner distinct from that of CA-4 and of 4, 6, and 9.
We next used molecular docking studies to investigate the binding of 8 to the tubulin dimer. 
Our goal was to determine whether the compound(s) might have distinct binding properties 
that could explain the different antimicrotubule effects of compounds 4 and 8, as well as 
colchicine, on tumor cells.
Computer Modeling
The theoretical binding mode of TEDB-TBs at the CS in the tubulin dimer was investigated 
by using entry 1SA0 in the Protein Data Bank as a structure of the αβ-tubulin dimer. In this 
crystal structure, N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine), a close 
analogue of colchicine, was used to illustrate its binding to the CS.23 Colchicine is known to 
bind at the interface between the α- and β-subunits, extending toward the β-subunit 
(Supporting Information, Figure S3A).24 Loop 7 (T7), strands 8 and 9, as well as helixes 7 
and 8 (H7 and H8), where the β-subunit connects to loop 5 (T5) of the α-subunit, are critical 
for interactions of ligand and protein in the CS. We previously reported15 that the 
benzo[b]thiophenyl B-ring of 4 and the colchicine A-ring showed common pharmacophores 
acting as hydrophobic centers. The overlapped 3D model of 4 and colchicine (Figure 7A) 
also supported this prior finding, showing that both rings were oriented in the same 
direction. This partial similarity in the 3D model complemented the similar effects on 
inhibition of microtubule polymerization in a cell-free system (Table 1), as well as in 
cultured cells (Figure 5).
In the tubulin binding assay described above (Table 1), CA-4 inhibited 99% of colchicine 
binding to tubulin, while 4 or 8 inhibited 78% or 39%, respectively. Thus, we expected that 
4 and its hydroxyl analogues, especially 8, would show a different mode of binding to the 
CS. An overview of the binding modes of 4 and 8 in the crystal structure of the αβ-tubulin 
dimer did show overlap with DAMA-colchicine (Figure 7B). However, as expected, a 
detailed docking model of 4 (Figure 8A) revealed a considerable difference from that of 
DAMA-colchicine (Supporting Information, Figure S3A), and 8 also showed a distinct 
binding mode (Figure 8B–D and Supporting Information, Figure S3B). The 
benzo[b]thiophenyl B-ring of 4 was located in the pocket on β-tubulin. Accordingly, any 
substituents on this ring might directly affect the binding affinity with amino acid(s) on β-
tubulin and the shape of the binding pocket. The unsaturated A-ring of 4 was positioned 
toward α-tubulin, with the C-6 ethyl group forced into the open space between α- and β-
tubulin, while the C-8 geminal ethyl groups were held entirely in β-tubulin. While the 3-
methoxy group on colchicine’s A-ring generates an important interaction with the side chain 
of Cys241 in β-tubulin (βCys241) (note that numbering of β-tubulin residues follows the 
modeling convention used in ref 23 rather than the actual sequence numbers) (Supporting 
Information, Figure S3A),23 neither of the TEDB-TB analogues interacted with βCys241. 
Instead, the docked model of analogue 4 showed H-bonds with the side chains of αAsn101, 
αSer178, and αThr179 (Figure 8A). With analogue 8, the side chain of βVal238 formed an 
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H-bond with the C-6′ hydroxyl group; however, the H-bond found between the C-7 oxygen 
of 4 and αAsn101 was not present (Figure 8B–D and Supporting Information, Figure S3B). 
We made the following conclusions based on the docking models of 4 and 8: (1) Bioactive 
TEDB-TBs 4 and 8 have two oxygen atoms on C-4 and C-5 in the chromone skeleton, and 
the C-4 and C-5 oxygen atoms form H-bonds with αSer178 and αThr179, respectively. (2) 
The H-bond between αAsn101 and the C-7 oxygen atom of 4 could be a critical factor for 
inhibition of tubulin polymerization. (3) The force of the H-bond between βVal238 and the 
C-6′ hydroxyl group of 8 could prevent formation of the H-bond with αAsn101 observed in 
4.
The models for the binding of TEDB-TBs to tubulin show great dependence on amino acid 
residues of the α-tubulin, rather than the β-tubulin, subunit, which differs from other CS 
agents and, thus, could explain some of the properties of the TEDB-TBs. All four hydroxyl 
benzo[b]thiophen-3-yl analogues 6–9 and lead compound 4 bound in the same place on 
tubulin with similar docking structures, although the 7′-OH analogue 9 was slightly shifted 
from the docking pattern of the other compounds (Figure 9A,B). This difference indicated 
that the binding pocket around the 7′-position either did not have enough space to 
accommodate a hydroxyl group or generated an electronic disruption.
Unexpectedly, the distance between the A-ring carbonyl oxygen on 9 and the nitrogen on 
αAsn101 (N-O distance) was not large (3.076 Å), despite the slight shift in the docking 
mode of 9 as described above. Furthermore, analogue 6 displayed the smallest N-O distance 
(2.563 Å), although an unsuitable N-H···O angle (111.6°) appeared to prevent H-bond 
formation. For 4, the N-O distance was 3.091 Å, which is more than 0.8 Å shorter than that 
of 8 (Figure 9D). Accordingly, analogues 4 and 6 were located closer to αAsn101 than 
analogues 7 and 8 (Figure 9C). This result might explain why analogues 4 and 6 exhibited 
greater tubulin depolymerization activity than analogues 7 and 8. The distinction between 
the H-bonding modes of 4 and 8 might be relevant to their distinct antimicrotubule activities 
in cultured cells. Accordingly, like CA-4, compounds 4 and 6 disrupted interphase 
microtubule dynamics as well as spindle formation, while interphase microtubules were 
intact in cells treated with 7 and 8 at the effective dose that induced cell cycle arrest by 
inhibiting spindle formation (Figure 6).
Finally, it should be noted that the C-7′ methoxy group in analogue 12 appeared to be 
located similarly to, but about 2 Å inside, an A-ring methoxy group on colchicine. Thus, the 
7′-OMe group might be too close to the βVal238 and βThr239 positions and could disturb 
the binding affinity (Supporting Information, Figure S4).
In summary, hydroxyl- or methoxy-substituted TEDB-TB analogues 6–20 were synthesized 
and evaluated for in vitro antiproliferative activity, for effects on cell cycle progression, and 
for interactions with purified tubulin. Hydroxyl naphthalene derivatives 15 and 16 inhibited 
growth of multiple tumor cell lines more strongly than their parent compound 5. All 
hydroxyl analogues showed potent antiproliferative activity, while methoxy analogues were 
less active. Active analogues induced cell cycle arrest at the G2/M phase, especially at the 
prometaphase by disrupting spindle formation. All cytotoxic hydroxyl analogues targeted 
tubulin. Molecular modeling indicated that the hydroxyl benzo[b]thiophene analogues 
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interacted with the CS in distinct binding modes. Disruption of interphase microtubules by 
the benzo[b]thiophene analogues was altered by modification of the parent compound with 
hydroxyl groups in a site-dependent manner.
Computational docking models suggested that all TEDB-TB analogues bound to the tubulin 
heterodimer at the CS, but considerable differences were observed in H-bond formations 
with CS amino acids. This binding mode diversity could be attributable to the modification 
of the benzo[b]thiophene moiety with hydroxyl groups. In particular, αAsn101, αSer178, 
and αThr179 and βVal238 contributed to stable H-bonds with TEDB-TB analogues. 
Compound 4, which disrupted both interphase microtubules and mitotic spindle formation, 
and compound 8, which disrupted only spindle formation, formed H-bonds with only α-
tubulin or with both α- and β-tubulin, respectively. Thus, we speculate that interphase 
microtubule dynamics are less affected or even not disrupted at all when a TEDB-TB 
analogue/ligand, such 8, formed several H-bonds with both α- and β-tubulin.
While clinically successful tubulin inhibitors target both the mitotic spindle and interphase 
microtubules in chemosensitive cancer cells, some of our new analogues effectively 
inhibited bipolar spindle formation without interfering with interphase microtubule 
dynamics in both chemosensitive and MDR cancer cells. Therefore, these TEDB analogues 
might be promising candidates leading to a new chemotherapeutic drug targeted at tubulin 
and also could possibly overcome MDR obstacles, as well as reducing undesirable effects in 
slowly growing normal cells.
3. EXPERIMENTAL SECTION
All chemicals and solvents were used as purchased. All melting points were measured on a 
Fisher-Johns melting point apparatus and are reported without correction. 1H and 13C NMR 
spectra were recorded on a Varian Gemini 2000 (300 MHz) or Varian Inova (400 MHz) 
NMR spectrometer with TMS as the internal standard. All chemical shifts are reported in 
ppm. NMR spectra are referenced to the residual solvent peak, chemical shifts δ are in ppm, 
and apparent scalar coupling constants J are in hertz. Mass spectroscopic data were obtained 
on a Shimadzu LCMS-IT-TOF instrument. Analytical thin-layer chromatography (TLC) was 
carried out on Merck precoated aluminum silica gel sheets (Kieselgel 60 F-254). Biotage 
Flash or Isco Companion systems were used for flash chromatography. All target 
compounds were characterized and determined to be at least >95% pure by 1H NMR and 
analytical HPLC.
General Synthetic Procedures for 22
A solution of 21 in EtOH-50% aq KOH (1:1, v/v) and an appropriate aromatic aldehyde 
(excess) was stirred at room temperature. After the reaction was complete, as judged by 
TLC analysis, the mixture was poured into ice-cold 1 N HCl and then extracted with 
CH2Cl2. The extract was washed with brine, dried over Na2SO4, and concentrated in vacuo. 
The residue was chromatographed on silica gel with CH2Cl2-hexane as eluent to afford the 
target compound 22 in 78%-95% yield (based on recovery of starting material).
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General Synthetic Procedures for 4–20
Compound 22 was dissolved in DMSO containing 1% H2SO4, then I2 (0.1 mol equiv) was 
added. The mixture was heated at 90 °C for 1 h. The reaction mixture was quenched with 
ice-cold aqueous 10% Na2S2O3 and extracted three times with EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
residue was purified by silica gel chromatography with EtOAc–hexane as eluent to afford 
crude compound 23, which was dissolved in anhydrous CH2Cl2. BBr3 (3 mol equiv, 1.0 M 
solution in CH2Cl2) was added to the solution at 0 °C, which was allowed to warm to rt and 
stirred overnight. After addition of water, the reaction mixture was extracted three times 
with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4, and 
concentrated in vacuo. The residues were chromatographed on silica gel, eluting with 
EtOAc-hexane (1:4) to obtain analogues 6–9, 14–16, and 19, as well as 10–12, 17, and 20 as 
minor products.
2-(4′-Hydroxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmos-dumotin B (6)
1H NMR (300 MHz, CDCl3, δ): 13.12 (s, 1H, chelated-OH), 7.75 (s, 1H, 2′-H), 7.61 (d, 1H, 
J = 8.0 Hz, 5′ or 7′-H), 7.31 (dd, 1H, J = 7.8 and 8.0 Hz, 6′-H), 6.99 (s, 1H, 3-H), 6.90 (d, 
1H, J = 7.8 Hz, 5′ or 7′-H), 2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.21-2.10 (m, 2H, 8-
CH2CH3), 2.03-1.91 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.68 (t, 6H, J 
= 7.3 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C23H23O5S, 411.1261; found, 
411.1249.
2-(5′-Hydroxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmos-dumotin B (7)
1H NMR (300 MHz, CDCl3, δ): 13.10 (s, 1H, chelated-OH), 8.08 (s, 1H, 2′-H), 7.80 (d, 1H, 
J = 8.7 Hz, 7′-H), 7.57 (d, 1H, J = 2.3 Hz, 4′-H), 7.10 (dd, 1H, J = 8.7 and 2.3 Hz, 6′-H), 
6.95 (s, 1H, 2-H), 5.55 (s, 1H, 5′-OH), 2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.34-2.23 (m, 
2H, 8-CH2CH3), 2.06-1.96 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 
(t, 6H, J = 7.3 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C23H23O5S, 411.1261; 
found, 411.1258.
2-(6′-Hydroxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmos-dumotin B (8)
1H NMR (300 MHz, CDCl3, δ): 13.11 (s, 1H, chelated-OH), 7.94 (d, 1H, J = 8.8 Hz, 4′-H), 
7.88 (s, 1H, 2′-H), 7.41 (d, 1H, J = 2.3 Hz, 7′-H), 7.12 (dd, 1H, J = 8.8 and 2.3 Hz, 5′-H), 
6.90 (s, 1H, 3-H), 5.62 (s, 1H, 6′-OH), 2.48 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.34-2.21 (m, 
2H, 8-CH2CH3), 2.05-1.94 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.71 
(t, 6H, J = 7.4 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C23H23O5S, 411.1261; 
found, 411.1258.
2-(7′-Hydroxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmos-dumotin B (9)
1H NMR (300 MHz, CDCl3, δ): 13.12 (s, 1H, chelated-OH), 8.07 (s, 1H, 2-H), 7.68 (d, 1H, 
J = 8.1 Hz, 4′-H), 7.43 (dd, 1H, J = 7.8 and 8.1 Hz, 5′-H), 6.94 (s, 1H, 3-H), 6.92 (d, 1H, J = 
7.8 Hz, 6-H), 6.10 (s, 1H, 7′-OH), 2.48 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.34-2.12 (m, 2H, 8-
CH2CH3), 2.08-1.96 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.72 (t, 6H, J 
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= 7.4 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C23H23O5S, 411.1261; found, 
411.1250.
2-(4′-Methoxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldes-mosdumotin B (10)
1H NMR (300 MHz, CDCl3, δ): 13.21 (s, 1H, chelated-OH), 7.66 (s, 1H, 2′-H), 7.53 (d, 1H, 
J = 8.0 Hz, 7′-H), 7.42 (t, 1H, J = 8.0 Hz, 6′-H), 6.88 (d, 1H, J = 8.0 Hz, 5′-H), 6.71 (s, 1H, 
3-H), 3.85 (s, 3H, 4′-OCH3), 2.47 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.19-2.09 (m, 2H, 8-
CH2CH3), 1.94-1.83 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.68 (t, 6H, J 
= 7.4 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C24H25O5S, 425.1417; found, 
425.1415.
2-(5′-Methoxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldes-mosdumotin B (11)
1H NMR (300 MHz, CDCl3, δ): 13.10 (s, 1H, chelated-OH), 8.05 (s, 1H, 2′-H), 7.82 (d, 1H, 
J = 8.9 Hz, 7′-H), 7.49 (t, 1H, J = 2.3 Hz, 4-H), 7.15 (dd, 1H, J = 8.9 and 2.3 Hz, 6′-H), 6.89 
(s, 1H, 3-H), 3.91 (s, 3H, 5′-OCH3), 2.47 (q, 2H, J = 7.5 Hz, 6-CH2CH3), 2.34-2.22 (m, 2H, 
8-CH2CH3), 2.07-1.96 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.5 Hz, 6-CH2CH3), 0.71 (t, 
6H, J = 7.5 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C24H25O5S, 425.1417; 
found, 425.1402.
2-(7′-Methoxybenzo[b]thiophen-3′-yl)-6,8,8-triethyldes-mosdumotin B (12)
1H NMR (300 MHz, CDCl3, δ): 13.10 (s, 1H, chelated-OH), 8.05 (s, 1H, 2′-H), 7.68 (d, 1H, 
J = 8.2 Hz, 7′-H), 7.51 (dd, 1H, J = 7.8 and 8.2 Hz, 6′-H), 6.93 (s, 1H, 3-H), 6.93 (d, 1H, J = 
7.8 Hz, 5′-H), 4.06 (s, 3H, 7′-OCH3), 2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.32-2.21 (m, 
2H, 8-CH2CH3), 2.06-1.94 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 
(t, 6H, J = 7.3 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C24H25O5S, 425.1417; 
found, 425.1420.
2-(3′-Hydroxybenzo[b]thiophen-2′-yl)-6,8,8-triethyldesmos-dumotin B (14)
1H NMR (300 MHz, CDCl3, δ): 12.81 (s, 1H, chelated-OH), 11.65 (br s, 1H, 3′-OH), 
8.23-8.17 (m, 1H), 8.04 (s, 1H, 3-H), 7.84-7.79 (m, 1H), 7.59-7.53 (m, 2H), 2.51 (q, 2H, J = 
7.5 Hz, 6-CH2CH3), 2.35-2.23 (m, 2H, 8-CH2CH3), 2.12-2.00 (m, 2H, 8-CH2CH3), 1.09 (t, 
3H, J = 7.5 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.5 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + 
H]+ calcd for C23H23O5S, 411.1261; found, 411.1251.
2-(4′-Hydroxynaphthalen-1′-yl)-6,8,8-triethyldesmosdumo-tin B (16)
1H NMR (300 MHz, CDCl3, δ): 13.25 (s, 1H, chelated-OH), 8.41-8.36 (m, 1H, 
naphthalenyl-H), 7.98-7.92 (m, 1H, naphthalenyl-H), 7.65-7.58 (m, 2H, naphthalenyl-H), 
7.56 (d, 1H, J = 8.0 Hz, naphthalenyl-H), 6.97 (d, 1H, J = 8.0 Hz, naphthalenyl-H), 6.79 (s, 
1H, 3-H), 6.70 (br s, 1H, 4′-OH), 2.50 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.26-2.16 (m, 2H, 8-
CH2CH3), 1.99-1.88 (m, 2H, 8-CH2CH3), 1.07 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.73 (t, 6H, J 
= 7.4 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C25H25O5, 405.1696; found, 
405.1680.
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2-(6′-Hydroxynaphthalen-2′-yl)-6,8,8-triethyldesmosdumo-tin B (19)
1H NMR (300 MHz, 3%CD3OD/CDCl3, δ): 13.21 (s, 1H, chelated-OH), 8.23 (br s, 1H, 
naphthalenyl-H), 7.87 (d, 1H, J = 8.8 Hz, naphthalenyl-H), 7.80 (d, 1H, J = 8.8 Hz, 
naphthalenyl-H), 7.72 (dd, 1H, J = 8.8 and 1.9 Hz, naphthalenyl-H), 7.26-7.19 (m, 2H, 
naphthalenyl-H), 6.98 (s, 1H, 3-H), 2.48 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.35-2.24 (m, 2H, 
8-CH2CH3), 2.13-2.01 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.70 (t, 
6H, J = 7.4 Hz, 8-CH2CH3 × 2). HRMS (m/z): [M + H]+ calcd for C25H25O5, 405.1696; 
found, 405.1679.
Antiproliferative Activity Assay
All stock cell lines were grown in T-75 flasks at 37 °C with 5% CO2 in air. Freshly 
trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 4000-12 
000 cells per well (based on the doubling time of the cell line) with compounds. The highest 
concentration of DMSO in the cultures (0.1% v/v) was without effect on cell growth under 
the culture conditions used. After 72 h in culture with test compounds, attached cells were 
fixed with 50% trichloroacetic acid and then stained with 0.04% sulforhodamine B. After 
solubilizing the protein-bound dye with 10 mM Tris base, absorbance at 515 nm was 
measured using a microplate reader (ELx800, BioTek) with Gen5 software (BioTek). The 
mean IC50 is the concentration of agent that reduced cell growth by 50% compared with 
vehicle (DMSO) control under the experimental conditions used and is the average from at 
least three independent experiments with duplicate samples. All values presented in Table 1 
are statistically significant. The following human tumor cell lines were used in the assay: 
A549 (lung carcinoma), HepG2 (hepatocellular carcinoma), HCT-8 (colon 
adenocarcinoma), KB (originally isolated from epidermoid carcinoma of the nasopharynx), 
KB-VIN (VIN-resistant KB subline showing MDR phenotype by overexpressing P-gp), 
MCF-7 (estrogen-receptor-positive, HER2-negative breast cancer), PC-3 (androgen-
insensitive prostate cancer), SK-BR-3 (estrogen-receptor-negative, progesterone-receptor-
negative, HER2-overexpressing breast cancer), ZR-75-1 (estrogen-receptor-positive, HER2-
overexpressing breast cancer). All cell lines were obtained from the Lineberger 
Comprehensive Cancer Center (UNC-CH) or from ATCC (Manassas, VA), except KB-VIN, 
which was a generous gift of Prof. Y.-C. Cheng (Yale University). Cells were cultured in 
RPMI-1640 medium supplemented with 2 mM L-glutamine and 25 mM HEPES (HyClone), 
supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 100 µg/mL 
streptomycin, 100 IU/mL penicillin, and 0.25 µg/mL amphotericin B (Cellgro). MDR stock 
cells (KB-VIN) were maintained in the presence of 100 nM VIN.
Tubulin Assays
Inhibitory effects of compounds against electro-phoretically homogeneous bovine brain 
tubulin were as described previously.25,26 Tubulin assembly assay mixtures contained 1.0 
mg/mL (10 µM) tubulin and varying compound concentrations and were preincubated for 15 
min at 30 °C without guanosine 5′-triphosphate (GTP). The samples were placed on ice, and 
0.4 mM GTP was added. Reaction mixtures were transferred to 0 °C cuvettes, and turbidity 
development was followed for 20 min at 30 °C following a rapid temperature jump. 
Compound concentrations as EC50 values that inhibited the increase in turbidity by 50% 
Nakagawa-Goto et al. Page 12
J Med Chem. Author manuscript; available in PMC 2016 March 12.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
relative to a control sample were determined. In colchicine inhibition assays, tubulin (1.0 
µM) was incubated with 5.0 µM [3H] colchicine and 5.0 µM test compound at 37 °C for 10 
min, when about 40–60% of maximum colchicine binding occurs in control samples.
Cell Cycle Analysis
Distribution of cells in the cell cycle was evaluated by measurement of the cellular DNA 
content by propidium iodide (PI) (BD Biosciences) staining. Briefly, cells were seeded in 
12-well culture plates 24 h prior to treatment with compounds. PXL was used at 0.02 or 3 
µM for chemosensitive (KB) or MDR (KB-VIN) cells, respectively. Both KB and KB-VIN 
cells were treated with 0.5 µM 4 or 2 µM 8, and vehicle (DMSO) was used as a control. For 
PC-3 cells, compounds 4 or 6–9 were used at 2 µM. After a 24 h treatment, supernatants and 
trypsinized cells were collected together, followed by centrifugation for 5 min at 1000 rpm. 
The pellet was resuspended with PBS and fixed in 70% EtOH overnight at −20 °C, followed 
by staining with PI overnight at 4 °C. Stained cells were analyzed by flow cytometry (FACS 
LSRII, BD Biosciences). Experiments were repeated a minimum of three times.
Immunofluorescence Staining
PC-3 cells were grown on an 8-well chamber slide (Lab-Tech) for 24 h prior to treatment 
with compound at equicytotoxic compound concentrations. The equi-cytotoxic compound 
concentrations were determined on the basis of their IC50 and/or the effective concentration 
used for cell cycle analysis as follows: 0.2 µM 4, 0.2 µM CA-4, 5 µM VIN, 0.2 µM PXL, 
and 1 µM colchicine (Figure 5 and Supporting Information, Figure S1). PC-3 cells were also 
treated with different doses of compounds 4 or 6–9 at 0.2, 2, and 20 µM. CA-4 was used at 
0.002, 0.02, and 20 µM (Figure 6 and Supporting Information, Figure S2). After treatment of 
cells with agent for 24 h, cells were fixed with 4% paraformaldehyde in PBS and 
permeabilized with 0.5% Triton X-100 in PBS. Fixed cells were labeled with mouse 
monoclonal antibody to α-tubulin (B5-1-2, Sigma) and rabbit IgG to Ser10-phosphorylated 
histone H3 (p-H3) (#06570, EMD Millipore), followed by FITC-conjugated antibody to 
mouse IgG (Sigma) and Alexa Fluor 549-conjugated antibody to rabbit IgG (Life 
Technologies). Nuclei were labeled with DAPI (Sigma). Fluorescently labeled cells were 
observed using an Olympus BX61 fluorescence microscope (Olympus), and images were 
captured by an ORCA-R2 digital camera (Hamamatsu Photonics) with Volocity 5.5.2 
software (PerkinElmer Inc.). Microtubules, p-H3, and DNA were also detected using a 
confocal microscope (Zeiss, LSM700) with ZEN (black edition) software (Zeiss). Confocal 
images were stacked and merged using ZEN (black edition) software. Experiments were 
repeated at least twice for each compound at each concentration. Final images were prepared 
using Adobe Photoshop CS3.
Computer Modeling
Three-dimensional (3D) structures of tubulin-ligand complexes were predicted by GOLD 
5.1 software with default settings. The 3D structure of human tubulin (TUBA1A and 
TUBB2B) used in this study was constructed from a Protein Data Bank entry (PDB ID: 
1SA0).23 Missing hydrogen atoms in the crystal structure were computationally added by 
Hermes.28 The center of the active site was defined as the center of the ligand in 1SA0, and 
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the active site radius was set to 10.0 Å. For the docking calculations, the quantum 
chemically optimized structures of ligands were used as initial structures. The structural 
optimizations of ligands were carried out by B3LYP/6-311+G(df,p) using Gaussian 09, 
Revision B.01.29
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Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
CA-4 combretastatin A-4
CSA colchicine site agent
CS colchicine site
DAMA-colchicine N-deacetyl-N-(2-mercaptoacetyl)colchicine
DAPI 4′,6-diamidino-2-phenylindole
DesB desmosdumotin B
DMF N,N-dimethylformamide
H-bond hydrogen bond
IC50 concentration that inhibits 50% human tumor cell growth
ICB inhibition of colchicine binding
ITA inhibition of tubulin assembly
MDR multidrug resistance
PBS phosphate-buffered saline
P-gp P-glycoprotein
PXL paclitaxel
SAR structure–activity relationship
TEDB 6,8,8-triethyldesmosdumotin B
TEDB-TB 2-(benzo[b]thiophene-3′-yl)-6,8,8-triethyldesmosdumotin B
VIN vincristine
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Figure 1. 
Structures of desmosdumotin B and related bioactive analogues.
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Figure 2. 
Structures of TEDB-TB analogues.
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Figure 3. 
Structure-activity relationship of hydroxylated TEDB-TB analogues. SAR study shown in 
Table 1 summarized: (1) 4′-position ≈ 6′-position > 5′-position ≈ 7′-position against HCT-8 
and (2) H > OH against PC-3.
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Figure 4. 
Effect of compounds on the cell cycle distribution in MDR cells. Chemosensitive KB cell 
line (A) and its MDR subline (KB-VIN) (B) were treated with vehicle control (DMSO), 
PXL (0.02 µM for KB and 3 µM for KB-VIN), 4, or 8 for 6 or 24 h, as indicated. Cell cycle 
progression was analyzed by measuring DNA content using a flow cytometer. Cell cycle 
phases are indicated as G1 (2N), S, G2/M (4N), and sub-G1. PXL disrupted cell cycle 
progression in KB cells at 0.02 µM, while no significant effect was seen in KB-VIN cells, 
even at 3 µM. Accumulation of G2/M phase as well as S phase cells was observed in both 
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chemosensitive and MDR cells treated with 4 and 8 at the same concentrations in a time-
dependent manner.
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Figure 5. 
Disruption of microtubule morphology in PC-3 cells by small molecules. Prostate cancer 
cells (PC-3) were treated for 24 h with antimicrotubule agents as indicated (DMSO as 
vehicle control, 0.2 µM compound 4, 0.2 µM CA-4, 5 µM VIN, 0.2 µM PXL). Compounds 
were used at equitoxic compound concentrations and examined for disruption of 
microtubule dynamics within 24 h. Microtubules were visualized by immunofluorescence 
staining using monoclonal antibody to α-tubulin (upper panels), and DAPI was used for 
DNA staining (lower panels). In control cells treated with DMSO, bipolar spindle formation 
in mitotic cells (arrow) as well as microtubule (MT) networks in interphase cells (double 
arrow) were observed. Treatment with 4 induced depolymerization of cytosolic microtubules 
as well monopolar (arrow heads) or multipolar spindle formations in the G2/M-phase. 
Treatment with CA-4 led to both depolymerization of interphase microtubules and 
disruption of mitotic spindles (arrows). PXL inhibited the onset of mitosis and arrested cells 
at prometaphase with condensed chromosomes (right panels). Characteristic bundled 
microtubules were observed in interphase cells treated with PXL, while tubulin paracrystal 
formation was observed in cells treated with VIN. Bar, 25 µm. Additional images including 
colchicine treatment are shown in the Supporting Information (Figure S1).
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Figure 6. 
Distinct effects on microtubule morphology by structural modification of compounds. (A) 
Effect of compounds on cell cycle distribution in PC-3 cells. PC-3 cells were treated for 24 h 
with 2 µM 4, 6, 7, 8, or 9 or vehicle control (DMSO), as indicated. Cell cycle progression 
was analyzed by flow cytometric analysis. All analogues efficiently induced accumulation 
of G2/M phase cells. (B) Dose-dependent effects of compounds on microtubule morphology 
in PC-3 cells. PC-3 cells were treated for 24 h with 4, 6, 7, 8, or 9 at 0.2, 2, or 20 µM. 
DMSO was used with the control cells. CA-4 was used at 0.002 or 20 µM. Cells were 
stained with antibodies to α-tubulin (green) and Ser10-phosphorylated histone H3 (p-H3, 
red) as a mitotic marker and with DAPI for DNA (blue). Stacked and merged confocal 
images are presented. TEDB-TB analogues induced cell cycle arrest at prometaphase (p-H3-
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positive) by disrupting bipolar spindle formation. Immature multipolar spindles (white arrow 
heads) were formed in the cells treated with analogues but were undetectable after CA-4 
treatment. Dose-dependent disruption of both interphase microtubules and spindles was 
observed in cells treated with 4, 6, 9, or CA-4. In contrast, in cells treated with 7 or 8, 
normal interphase microtubules and disrupted spindles were visualized (yellow arrows). Bar, 
25 µm. (C) Higher magnification views. Bar, 10 µm. Additional images are shown in the 
Supporting Information (Figure S2).
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Figure 7. 
Predicted docking models for 4 and 8 binding to tubulin. (A) Structures and 3D models of 4 
(blue skeleton) and DAMA-colchicine (gray skeleton with oxygen in red, nitrogen in blue, 
and sulfur in yellow). (B) Docking model of 4 (blue skeleton), 8 (brown skeleton), and 
DAMA-colchicine (sphere in 3D with carbon in gray, proton in white, oxygen in red, 
nitrogen in blue, and sulfur in yellow) in the CS (yellow circle) of the tubulin crystal 
structure (PDB ID: 1SA0), shown as a ribbon diagram.
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Figure 8. 
Predicted docking models for 4 and 8 binding in the CS. Crystal structures (PDB ID: 1SA0) 
of α- (white) and β-tubulin (red) are shown as ribbon diagrams. H-bonds calculated to be 
less than 3 Å between protein and compounds are represented by dashed lines. Docking 
models of compounds (gray skeleton with oxygen in red and sulfur in yellow) 4 (A) and 8 
(B) in the CS are shown. Superimposition of docked compound 4 shows H-bonds with the 
side chains of αAsn101 (dashed blue circle) and αSer178 and αThr179 (dashed green 
circle). In contrast, with 8, there is a H-bond between 8 and the side chain of βVal238 
(dashed white circle), and the H-bond between 8 and the side chain of αAsn101 is absent. 
(C) Docking mode of 8 in the CS. Superimposition of docked compound 8 shows H-bonds 
between 8 and αSer178 and αThr179 in α-tubulin (αSer178, αThr179) and between 8 and 
βVal238. (D) Comparison of the docking mode of 8 (brown) with that of 4 (blue) in CS. 
Superimposition of docked compounds 4 and 8 shows conserved H-bonds with αSer178 and 
αThr179 (dashed green circle). An additional H-bond between the C-7 oxygen of 4 and 
αAsn101 (dashed blue circle) was also observed. In contrast, a H-bond between the C-6′ 
hydroxyl group of 8 and the side chain of βVal238 (white circle) was unambiguous, while 
no H-bond occurred with αAsn101.
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Figure 9. 
Hydrogen bonds between 4 analogues and tubulin in the CS. Structures (A) and 
conformations (B) of 4 and analogues are presented. The same docking pattern is shown 
among all compounds, except 9. (C) H-bond between C-7 oxygen of compounds and 
αAsn101. A H-bond calculated as less than 3 Å occurred in 4 and 6. (D) Comparison of 
distance between oxygen on compound and nitrogen on αAsn101. The N-O distances for 4 
(3.091 Å) and 8 (3.963 Å) differed by over 0.8 Å.
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Scheme 1. 
Syntheses of New Analogues of 4 and 5a
aReagents and conditions: (a) ArCHO, 50% KOH, EtOH, rt; (b) I2 (cat.), DMSO, H2SO4 
(cat.), 90–95 °C, 1 h; (c) BBr3, 0 °C to rt.
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Scheme 2. 
Preparation of Methoxybenzothiophenecarboxaldehydesa
aReagents and conditions: (a) CH3COCH2Cl, K2CO3, DMF, rt; (b) PPA, 100 °C; (c) NBS, 
(PhCOO)2, CCl4, reflux; (d) HMTA, CHCl3, reflux, then 50% HOAc, reflux; (e) NaOMe, 
CuO, CuI, KI, DMF, reflux; (f) n-BuLi, THF, −78 °C, then DMF.
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